Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
about
Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining ConditionsManagement of HCV-Associated Liver Cirrhosis.Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise reviewKASL clinical practice guidelines: management of hepatitis CDirect anti-HCV agentsProfile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infectionRole of liver transplantation in human immunodeficiency virus positive patientsImpact of new treatment options for hepatitis C virus infection in liver transplantationHepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?Sofosbuvir/velpatasvir: A promising combinationAlcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infectionsTreatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug TherapySystematic review and meta-analysis of hepatitis C virus infection and HIV viral load: new insights into epidemiologic synergyClinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis CPotential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected PatientsTreatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis CTreatment optimization for HIV/HCV co-infected patients.HIV, Aging, and Viral Coinfections: Taking the Long View.Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.Hepatitis C in a New Era: A Review of Current TherapiesBarriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era.Highly Successful Hepatitis C Virus (HCV) Treatment Outcomes in Human Immunodeficiency Virus/HCV-Coinfected Patients at a Large, Urban, Ryan White Clinic.Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study.Use of transient elastography in patients with HIV-HCV coinfection: A systematic review and meta-analysisGenotypic distribution and hepatic fibrosis among HIV/HCV co-infected individuals in Southern China: a retrospective cross-sectional studyDimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain.Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study.Human immunodeficiency virus and liver disease: An update.Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis.Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study.Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations.Recent advances in management of the HIV/HCV coinfected patient.How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence.Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV.12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.On-Treatment Elevation in Hepatic Transaminases during HCV Treatment with Ombitasvir, Paritaprevir, Dasabuvir, Ritonavir, and Ribavirin: A Case Series.
P2860
Q26740117-1A2349AA-3F29-48D7-9437-5A5C24FF890EQ26740320-72303493-FE6C-4967-9594-C739B7D445C6Q26747705-06881167-32B6-45CB-A17A-EF82A268D7B1Q26752471-D458697C-72FE-43CF-8C9E-B03A2427B0F7Q26767329-3DF7CEEE-56F1-437F-BB0F-294AAE0F4E27Q26775825-D0750479-30A7-4BBE-9B19-6198545ACD27Q26775931-EDDB7F90-3CCD-435B-9A6E-69E53B0E755CQ26782017-50DB7CFC-1CD7-4F83-9D97-957C86B09787Q26801828-EA0FCAA8-6329-4B5E-95EA-B5555444E980Q27468954-F2A1CE59-72D9-4BF2-A343-CC01543347ADQ28070280-2EE6A74D-3E7A-4C07-BBDD-1E0F1BE039C7Q28073100-00A97A50-8A3B-4A22-B4AF-67A6F06F15FCQ28077305-00EA99DF-E4F9-4201-9630-404C5982AF9EQ28080225-AC4D7893-70EF-455F-852B-5C91304F4671Q28550423-D4A8493C-75A2-487A-B191-4E4E7D59AA3BQ28552691-3E96FB9C-3782-4D94-88BB-99621AD33E37Q30235034-08E8C245-7629-4B27-9291-327428CA1D15Q30245486-2F542CFF-2FEB-4ED0-A451-3D2F3FED2901Q33557819-DD287B93-6615-43D0-B7C3-C714DF49F9C9Q33585021-848B14B0-62BE-4919-BFD1-E66DEF9A492FQ33629538-F59C7F62-4C67-410B-8466-95978333D07BQ33647154-6F802F12-AA33-4FCB-9F0F-9E4C0AFF81C7Q33699364-68FB0F2C-4425-4F41-8920-DC99DD5FEE73Q33883646-45083844-B359-41D0-81F5-7CB7A5D52FDAQ35948551-50F16F3F-FE78-425E-882E-F35B726F34AAQ36110233-57EDA0C5-FB8C-4E81-ABEA-6B5147CCD886Q36167452-8255B065-4713-4085-9D69-9C9162950DE1Q36327141-DD59896B-3394-4BB4-80C0-E0A4462ABDF5Q36330435-7E5BF2E0-ED95-44AD-99F6-AD93801AFD37Q36378109-B04802E5-AF94-4D33-94E7-FFB2D6A07B00Q36399193-B017C84F-09CE-487A-8632-3C383E651136Q36459660-010FD235-F714-4BAF-8EDF-10281D9FD4DFQ36519126-E8578846-085C-4042-9761-1D8D4A922577Q36575497-F6D9875E-711D-4265-A973-0014F3FC6FF0Q36676374-21FE59A2-96A3-41CC-9D02-CF2F25F11DAAQ36837502-B24A92B4-A6CC-4125-8A4C-61C306045029Q36875036-6520C1EA-EEFA-4586-BCA1-EC9A220D5C31Q36948099-19529CC7-32C5-49BC-B3C2-949DBFF0C550Q36948115-FDB09B07-9BEF-4D37-A1D0-8BC672BB3282Q36985508-34249F61-F4AC-48AE-9BB1-B91008894EA5
P2860
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Ombitasvir, paritaprevir co-do ...... ith HIV-1: a randomized trial.
@en
type
label
Ombitasvir, paritaprevir co-do ...... ith HIV-1: a randomized trial.
@en
prefLabel
Ombitasvir, paritaprevir co-do ...... ith HIV-1: a randomized trial.
@en
P2093
P50
P921
P356
P1476
Ombitasvir, paritaprevir co-do ...... ith HIV-1: a randomized trial.
@en
P2093
Amit Khatri
Andrew L Campbell
Barbara Da Silva-Tillmann
Barbara McGovern
Fritz Bredeek
Gary Blick
Gretja Schnell
Jay Lalezari
Jihad Slim
P304
P356
10.1001/JAMA.2015.1328
P407
P577
2015-03-01T00:00:00Z